AlloMek Therapeutics
Farmington
About AlloMek Therapeutics
Allomek Therapeutics is a privately held pharmaceutical company committed to helping cancer patients by the discovery and development of targeted therapies. Allomek’s primary interest lies in the inhibition of targets associated with the Ras pathway. Allomek has discovered a novel class of MEK kinase inhibitors that improve the biopharmaceutical properties of previous MEK inhibitors. Allomek’s clinical candidate, CIP-1374, is an allosteric MEK kinase inhibitor that combines potent activity against MEK1/2 kinase and against chemo-resistant ovarian cancer stem cells.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $150.0K
- Funding stage: M&A
- Last round: Pre-Seed (May 2013)
- Website: allomek.optimatrix.net
- Phone: 203-208-2811
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/allomek-therapeutics-1536742 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.